106 related articles for article (PubMed ID: 20130876)
1. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Ko AH; Venook AP; Bergsland EK; Kelley RK; Korn WM; Dito E; Schillinger B; Scott J; Hwang J; Tempero MA
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1051-7. PubMed ID: 20130876
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
Smith DA; Conkling P; Richards DA; Nemunaitis JJ; Boyd TE; Mita AC; de La Bourdonnaye G; Wages D; Bexon AS
Cancer Immunol Immunother; 2014 Aug; 63(8):787-96. PubMed ID: 24770667
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
Nimeiri HS; Oza AM; Morgan RJ; Friberg G; Kasza K; Faoro L; Salgia R; Stadler WM; Vokes EE; Fleming GF; ; ;
Gynecol Oncol; 2008 Jul; 110(1):49-55. PubMed ID: 18423560
[TBL] [Abstract][Full Text] [Related]
4. Developments in metastatic pancreatic cancer: is gemcitabine still the standard?
Ying JE; Zhu LM; Liu BX
World J Gastroenterol; 2012 Feb; 18(8):736-45. PubMed ID: 22371633
[TBL] [Abstract][Full Text] [Related]
5. Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.
Patnaik A; Weiss GJ; Papadopoulos KP; Hofmeister CC; Tibes R; Tolcher A; Isaacs R; Jac J; Han M; Payumo FC; Cotreau MM; Ramanathan RK
Br J Cancer; 2014 Jul; 111(2):272-80. PubMed ID: 24901237
[TBL] [Abstract][Full Text] [Related]
6. Role of erlotinib in the management of pancreatic cancer.
Starling N; Neoptolemos J; Cunningham D
Ther Clin Risk Manag; 2006 Dec; 2(4):435-45. PubMed ID: 18360654
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.
Hosein PJ; de Lima Lopes G; Pastorini VH; Gomez C; Macintyre J; Zayas G; Reis I; Montero AJ; Merchan JR; Rocha Lima CM
Am J Clin Oncol; 2013 Apr; 36(2):151-6. PubMed ID: 22307213
[TBL] [Abstract][Full Text] [Related]
8. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.
Bodoky G; Timcheva C; Spigel DR; La Stella PJ; Ciuleanu TE; Pover G; Tebbutt NC
Invest New Drugs; 2012 Jun; 30(3):1216-23. PubMed ID: 21594619
[TBL] [Abstract][Full Text] [Related]
9. A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer.
Infante JR; Jones SF; Bendell JC; Spigel DR; Yardley DA; Weekes CD; Messersmith WA; Hainsworth JD; Burris HA
Eur J Cancer; 2011 Jan; 47(2):199-205. PubMed ID: 21051221
[TBL] [Abstract][Full Text] [Related]
10. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
[TBL] [Abstract][Full Text] [Related]
11. KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.
Boeck S; Jung A; Laubender RP; Neumann J; Egg R; Goritschan C; Ormanns S; Haas M; Modest DP; Kirchner T; Heinemann V
J Gastroenterol; 2013 Apr; 48(4):544-8. PubMed ID: 23435671
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in targeted therapy for pancreatic adenocarcinoma.
Fang YT; Yang WW; Niu YR; Sun YK
World J Gastrointest Oncol; 2023 Apr; 15(4):571-595. PubMed ID: 37123059
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities.
Arias-Pinilla GA; Modjtahedi H
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917882
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic Cancer: Recent Progress of Drugs in Clinical Trials.
Zhang Z; Song J; Xie C; Pan J; Lu W; Liu M
AAPS J; 2021 Feb; 23(2):29. PubMed ID: 33580411
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions.
Strapcova S; Takacova M; Csaderova L; Martinelli P; Lukacikova L; Gal V; Kopacek J; Svastova E
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32707920
[TBL] [Abstract][Full Text] [Related]
16. Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis.
van Mackelenbergh MG; Stroes CI; Spijker R; van Eijck CHJ; Wilmink JW; Bijlsma MF; van Laarhoven HWM
Cancers (Basel); 2019 Apr; 11(5):. PubMed ID: 31035512
[TBL] [Abstract][Full Text] [Related]
17. Application of preoperative three-dimensional model design in radioactive particle implantation for advanced pancreatic cancer.
Liu Y; Lyu SC; Wang XQ; Wang YB
Onco Targets Ther; 2018; 11():8685-8693. PubMed ID: 30584326
[TBL] [Abstract][Full Text] [Related]
18. Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?
Hua J; Shi S; Liang D; Liang C; Meng Q; Zhang B; Ni Q; Xu J; Yu X
Onco Targets Ther; 2018; 11():4591-4608. PubMed ID: 30122951
[TBL] [Abstract][Full Text] [Related]
19. Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial.
Dittrich C; Königsberg R; Mittlböck M; Geissler K; Sahmanovic-Hrgovcic A; Pleiner-Duxneuner J; Czejka M; Buchner P
Invest New Drugs; 2019 Feb; 37(1):127-138. PubMed ID: 29998365
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Chiramel J; Backen AC; Pihlak R; Lamarca A; Frizziero M; Tariq NU; Hubner RA; Valle JW; Amir E; McNamara MG
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28445400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
